Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

New Yorker Examines Causes Of Rising Health Care Costs; Highlights McAllen, Texas
In a recent New Yorker essay, physician Atul Gawande examines the rising cost of health care in the U.S. and how controlling those costs is a central issue as lawmakers prepare health care overhaul legislation. Gawande compares hospitals in McAllen, Texas -- which is in the county with the lowest household income nationwide but has one of the most expensive health care markets in the U.S. -- with hospitals in other parts of the country that have lower costs but higher quality of care. He writes, "McAllen and other cities like it have to be weaned away from their untenably fragmented, quantity-driven systems of health care, step by step," which means rewarding physicians and hospitals that "collaborate to increase prevention and the quality of care, while discouraging overtreatment, undertreatment and sheer profiteering" (Gawande, New Yorker, 6/1).
generic viagra online
Expert Statement Issued About Lantus(R) Following Recent Publications In Diabetologia
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the release of an Expert Statement by a multidisciplinary board of renowned international experts following an in-depth assessment of the recent publications of registry analyses with Lantus(R) (insulin glargine [rDNA] injection) in Diabetologia. This board of international specialists in the field of endocrinology, oncology and epidemiology came to the conclusion, that all four manuscripts have significant methodological limitations and shortcomings, and that they provide inconsistent and inconclusive results regarding a potential link between insulin glargine use and an increased risk of cancer.
News of the day
Sancuso(R) Clinical Trial Application Filed In China
Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the filing of clinical trial application (CTA) of SP-01 (long-acting transdermal granisetron patch; brand name: Sancuso®) to the China State Food and Drug Administration (SFDA). This represents the first regulatory-related filing in China made by Solasia. Upon SFDA approval of the application expected in the 1st quarter of 2010, Solasia will initiate Sancuso clinical trials in China through Excel PharmaStudies Inc. (http://www.excel-china.com), China"s largest Clinical Research Organization (CRO).
Endocrinology

AcroMetrix Announces The Release Of OptiQual(R) GBS Positive Control For Use With Diagnostic Assays That Detect Group B Streptococcus

AcroMetrix, a leading manufacturer of quality control standards and controls for clinical diagnostic and blood testing laboratories, announced the release of the first standardized quality control for molecular Group B Streptococcus (GBS) testing. The OptiQual GBS Positive Control is designed to help clinical laboratories comply with CLIA guidelines for qualitative molecular assays that detect Group B Streptococcus DNA, ensuring accuracy and precision throughout the testing procedure. Colonization of an expectant mother with Group B Streptococcus can pose an extreme threat to the newborn, potentially causing pneumonia, sepsis, or meningitis. In order to appropriately manage prevention of GBS transmission, obstetricians and labor and delivery nurses are beginning to utilize the more rapid and sensitive methods of PCR-based GBS detection. "As rapid, point-of-care molecular assays for Group B Streptococcus begin to replace the traditional culture-screening method, doctors and clinical laboratory technologists will want appropriate quality control materials to accurately monitor the performance of their assays," says Michael J. Eck, President and CEO of AcroMetrix. "Ultimately, the goal is for doctors to more efficiently administer antibiotic prophylaxis in order to prevent GBS transmission from a mother to her newborn. AcroMetrix is dedicated to helping doctors achieve this goal by providing quality control products such as the OptiQual GBS Positive Control." The OptiQual GBS Positive Control is unassayed and contains inactivated whole Group B Streptococcus bacteria, providing a safer method of monitoring the entire molecular testing procedure from extraction through amplification and detection. Convenient and ready to use, the OptiQual GBS Positive Control is stored at refrigerated temperatures. This product is for in vitro diagnostic use. OptiQual is a registered trademark of AcroMetrix. AcroMetrix


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009